The TRAVERSE trial, a large-scale clinical study with over 5,000 patients, published in 2023, concluded that TRT does not increase the risk of adverse cardiovascular outcomes in men with hypogonadism.

“As soon as I was diagnosed, I didn’t want anything. No information. They gave me a leaflet, and I put it in my bedside ...